Laboratory Co. of America Holdings (NYSE:LH) Shares Sold by Prudent Man Advisors LLC

Prudent Man Advisors LLC lowered its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 10.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,634 shares of the medical research company’s stock after selling 657 shares during the quarter. Prudent Man Advisors LLC’s holdings in Laboratory Co. of America were worth $1,292,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AMF Tjanstepension AB raised its stake in shares of Laboratory Co. of America by 37.0% during the 3rd quarter. AMF Tjanstepension AB now owns 86,026 shares of the medical research company’s stock worth $19,232,000 after buying an additional 23,221 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Laboratory Co. of America during the 3rd quarter worth $854,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Laboratory Co. of America by 28.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,313 shares of the medical research company’s stock worth $1,624,000 after buying an additional 1,624 shares during the last quarter. PFG Investments LLC acquired a new position in shares of Laboratory Co. of America during the 3rd quarter worth $223,000. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of Laboratory Co. of America by 17.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 20,204 shares of the medical research company’s stock worth $4,515,000 after buying an additional 3,048 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Activity at Laboratory Co. of America

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 1,000 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $235,000.00. Following the sale, the director now owns 12,722 shares in the company, valued at approximately $2,989,670. The trade was a 7.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Adam H. Schechter sold 6,121 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total value of $1,497,319.02. Following the completion of the transaction, the chief executive officer now owns 86,445 shares in the company, valued at $21,146,175.90. This represents a 6.61 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,372 shares of company stock valued at $5,175,793. Corporate insiders own 0.85% of the company’s stock.

Laboratory Co. of America Stock Performance

Laboratory Co. of America stock opened at $251.45 on Friday. The stock’s 50 day moving average price is $241.20 and its 200 day moving average price is $232.64. The firm has a market capitalization of $21.03 billion, a PE ratio of 28.51, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, sell-side analysts expect that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.15%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio is currently 32.65%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Morgan Stanley lifted their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Evercore ISI raised shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $260.00 to $265.00 in a research note on Tuesday, January 7th. Barclays cut their target price on shares of Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating for the company in a research note on Friday, February 7th. Jefferies Financial Group boosted their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, UBS Group cut their target price on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Laboratory Co. of America currently has an average rating of “Moderate Buy” and an average price target of $265.75.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.